Summary
Boston Scientific Corporation (BSX) announced a significant leadership transition within its Interventional Cardiology and Rhythm Management divisions through an 8-K filing on June 7, 2020. Kevin J. Ballinger, the current executive vice president and president of Interventional Cardiology, is set to resign effective July 3, 2020, to pursue a CEO role at a non-competing firm. This departure triggers a series of internal role changes aimed at ensuring continuity and leveraging existing talent within the company. Joseph M. Fitzgerald, previously leading Rhythm Management, will assume Mr. Ballinger's responsibilities in Interventional Cardiology, effective July 6, 2020. Complementing this, Scott Olson, currently senior vice president, commercial general manager of Rhythm Management, has been promoted to senior vice president and president of Rhythm Management. Importantly, Mr. Olson will also join Boston Scientific's Executive Committee, signifying increased leadership scope. In connection with his new role, Mr. Fitzgerald will receive stock options valued at $1.0 million, vesting in January 2023, underscoring the company's commitment to aligning executive incentives with long-term performance.
Key Highlights
- 1Kevin J. Ballinger, EVP and President of Interventional Cardiology, will resign effective July 3, 2020.
- 2Joseph M. Fitzgerald, currently EVP and President of Rhythm Management, will transition to EVP and President of Interventional Cardiology.
- 3Scott Olson, currently SVP, Commercial General Manager of Rhythm Management, will be appointed SVP and President of Rhythm Management.
- 4Scott Olson will also join Boston Scientific's Executive Committee, effective July 6, 2020.
- 5Joseph M. Fitzgerald will receive a stock option grant valued at $1.0 million upon assuming his new role, vesting in full on January 1, 2023.
- 6The changes are part of a planned leadership transition, with Mr. Ballinger leaving to become CEO of another company.